Compare Ascendis Pharma A/S (ASND) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Charter Communications Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Charter Communications Inc trades at $131.19 (market cap $16.08B). The key difference: Ascendis Pharma A/S and Charter Communications Inc are close in size by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| ASND | CHTR | |
|---|---|---|
Market Cap | $17.74B | $16.08B |
Sector | Health | Media |
52-Week High | $277.18 | $399.61 |
52-Week Low | $163.32 | $125.54 |
Enterprise Value | $18.11B | $112.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Charter Communications (CHTR) trades at $130.73, down 2.69% today, with a bearish technical signal and oversold short-term RSI. The stock shows extremely low valuation multiples (P/E 3.54, P/S 0.32) against solid profitability (ROE 30.23%, net margin 9.03%), while recent news highlights potential partnerships with SpaceX and acquisition interest from Comcast. Cash flow remains positive despite high capital expenditures, though revenue growth has stagnated near $54.8B annually.
CHTR presents a deep value opportunity with significant upside to the $204.67 consensus target, but high debt ($93.21B long-term) and competitive pressures in broadband/video markets pose risks. Investor sentiment is mixed amid earnings misses, yet analyst coverage leans bullish with 47% buy ratings. The stock's trajectory hinges on operational execution and strategic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
